DESTINY-Breast03 Phase 3 Study Results
Hospitalization-Related Endpoints
Parameter
DESTINY-Breast03
T-DXd
(n = 261)
T-DM1
(n = 263)
Subjects with hospitalization, n (%)
18 (6.9)
19 (7.2)
Median (range) time to first hospitalization, a days
219.5 (0-723)
60.0 (0-399)
Median (range) length of hospital stay, days
10.5 (1-181)
9.0 (2-25)
2 (0.8)
1 (0.4)
Died, n (%)
Discharged home, n (%)
15 (5.7)
16 (6.1)
Discharged to home health care, n (%)
1 (0.4)
1 (0.4)
T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan.
aTime to first hospitalization is defined as the time from the date of randomization to the date of the first hospitalization during the study treatment (from date of first dose to 47
days after last dose). Time for subjects whose first hospitalization date was prior to treatment start date was calculated as 0.
ESMO BC 2022 #1630 Oral
48
48
Ο
Daiichi-SankyoView entire presentation